Characterization and treatment challenges of pulmonary hypertension in methamphetamine users

Abstract

The World Health Organization pulmonary hypertension classification scheme provides a framework for evaluation and management of patients with pulmonary vascular disease. Methamphetamine is a recreational stimulant which causes cardiac and pulmonary vascular toxicity. We discuss three cases of methamphetamine users who presented with left ventricular systolic failure but on heart failure therapy developed features more consistent with pulmonary arterial hypertension (PAH) or combined pre-capillary and post-capillary pulmonary hypertension. All three were started on PAH treatment and showed clinical improvement in symptoms. These cases illustrate the difficulty with treating methamphetamine users with pulmonary hypertension who have been left out of randomized controlled trials. Consideration should be given to creating a clinical registry for patients with methamphetamine associated pulmonary hypertension to assist with best treatment strategies.

Keywords

• Pulmonary arterial hypertension
• Systolic heart failure
• Methamphetamine